PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB财报
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
PACB Q4 2025 Key Financial Metrics
营收
$44.6M
毛利润
$16.6M
营业利润
$-41.2M
净利润
$-40.4M
毛利率
37.1%
营业利润率
-92.3%
净利率
-90.4%
同比增长
13.8%
EPS
$-0.11
资金流向
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 2025 财务摘要
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported revenue of $44.6M (up 13.8% YoY) for Q4 2025, with a net profit of $-40.4M (down 1802.7% YoY) (-90.4% margin). Cost of goods sold was $28.1M, operating expenses totaled $57.8M.
核心财务指标
| 总营收 | $44.6M |
|---|---|
| 净利润 | $-40.4M |
| 毛利率 | 37.1% |
| 营业利润率 | -92.3% |
| 报告期 | Q4 2025 |
营收拆解
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 2025 revenue of $44.6M breaks down across 2 segments, led by Products at $39.0M (87.3% of total).
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Products | $39.0M | 87.3% |
| Service And Other | $5.7M | 12.7% |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 分部营收 — 季度趋势
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Service And Other) has evolved quarter over quarter.
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Products | $39.0M | $32.6M | $33.1M | $31.1M |
| Service And Other | $5.7M | $5.8M | $6.7M | $6.0M |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 年度营收
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $160.0M). Click any linked year to see what changed vs the prior 10-K.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 季度营收与净利润历史
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $44.6M | +13.8% | $-40.4M | -90.4% |
| Q3 2025 | $38.4M | -3.8% | $-38.0M | -98.9% |
| Q2 2025 | $39.8M | +10.4% | $-41.9M | -105.4% |
| Q1 2025 | $37.2M | -4.3% | $-426.1M | -1146.8% |
| Q4 2024 | $39.2M | — | $2.4M | 6.0% |
| Q3 2024 | $40.0M | -28.2% | $-60.7M | -151.9% |
| Q2 2024 | $36.0M | -24.3% | $-173.3M | -481.3% |
| Q1 2024 | $38.8M | -0.2% | $-78.2M | -201.4% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $38.8M | $36.0M | $40.0M | $39.2M | $37.2M | $39.8M | $38.4M | $44.6M |
| 同比增长 | -0.2% | -24.3% | -28.2% | N/A | -4.3% | 10.4% | -3.8% | 13.8% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.67B | $1.51B | $1.45B | $1.26B | $860.8M | $825.5M | $803.2M | $784.1M |
| 总负债 | $1.02B | $1.02B | $996.9M | $753.9M | $769.2M | $764.0M | $767.1M | $778.7M |
| 股东权益 | $649.0M | $492.7M | $453.1M | $506.6M | $91.6M | $61.5M | $36.1M | $5.3M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-75.7M | $-54.3M | $-45.5M | $-30.6M | $-44.1M | $-29.4M | $-18.7M | $-19.1M |